China Resources Pharmaceutical Group Limited (3320.HK)
3320.HK Stock Price Chart
Explore China Resources Pharmaceutical Group Limited interactive price chart. Choose custom timeframes to analyze 3320.HK price movements and trends.
3320.HK Company Profile
Discover essential business fundamentals and corporate details for China Resources Pharmaceutical Group Limited (3320.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
28 Oct 2016
Employees
72.70K
Website
https://www.crpharm.comCEO
Xiaosong Bai
Description
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
3320.HK Financial Timeline
Browse a chronological timeline of China Resources Pharmaceutical Group Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 26 Mar 2026
Dividend declared on 11 Sept 2025
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend will be paid on 31 Oct 2025.
Earnings released on 26 Aug 2025
EPS came in at $0.36 falling short of the estimated $0.42 by -13.80%, while revenue for the quarter reached $144.50B , beating expectations by +5.12%.
Dividend declared on 28 May 2025
A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 14 Jul 2025.
Earnings released on 26 Mar 2025
EPS came in at $0.13 falling short of the estimated $0.23 by -44.78%, while revenue for the quarter reached $137.35B , beating expectations by +9.05%.
Earnings released on 24 Oct 2024
EPS came in at $0.45 falling short of the estimated $0.46 by -2.43%, while revenue for the quarter reached $139.35B , beating expectations by +0.53%.
Dividend declared on 10 Sept 2024
A dividend of $0.09 per share was announced, adjusted to $0.09. The dividend was paid on 30 Oct 2024.
Dividend declared on 4 Jun 2024
A dividend of $0.17 per share was announced, adjusted to $0.17. The dividend was paid on 19 Jul 2024.
Earnings released on 26 Apr 2024
EPS came in at $0.19 falling short of the estimated $0.21 by -6.71%, while revenue for the quarter reached $130.46B , missing expectations by -6.06%.
Earnings released on 26 Oct 2023
EPS came in at $0.48 , while revenue for the quarter reached $138.94B , beating expectations by +2.01%.
Dividend declared on 5 Jun 2023
A dividend of $0.16 per share was announced, adjusted to $0.16. The dividend was paid on 21 Jul 2023.
Earnings released on 27 Apr 2023
EPS came in at $0.18 falling short of the estimated $0.24 by -24.83%, while revenue for the quarter reached $128.39B , missing expectations by -7.58%.
Earnings released on 30 Jun 2022
EPS came in at $0.48 surpassing the estimated $0.36 by +32.86%, while revenue for the quarter reached $125.72B , beating expectations by +2.71%.
Dividend declared on 6 Jun 2022
A dividend of $0.15 per share was announced, adjusted to $0.15. The dividend was paid on 25 Jul 2022.
Earnings released on 31 Dec 2021
EPS came in at $0.21 falling short of the estimated $0.22 by -3.77%, while revenue for the quarter reached $122.32B , beating expectations by +3.79%.
Earnings released on 30 Jun 2021
EPS came in at $0.39 falling short of the estimated $0.46 by -15.56%, while revenue for the quarter reached $114.49B , beating expectations by +5.75%.
Dividend declared on 2 Jun 2021
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 23 Jun 2021.
Earnings released on 31 Dec 2020
EPS came in at $0.11 falling short of the estimated $0.16 by -29.13%, while revenue for the quarter reached $111.04B , missing expectations by -19.80%.
3320.HK Stock Performance
Access detailed 3320.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.